N- and O-glycosylation muteins of recombinant human erythropoietin secreted
from BHK-21 cells
MR Fibi, P Hermentin, JU Pauly, L Lauffer and G Zettlmeissl
Research Laboratories of Behringwerke AG, Department of Preclinical
Research of Therapeutics, Marburg, Germany.
Single-site glycomuteins of recombinant human erythropoietin (rhuEpo) were
constructed and transiently and stably expressed in BHK-21 cells. The
transient expression levels varied among muteins, being highest for mutein
rhuEpoGln24 followed by wild-type rhuEpo (rhuEpowt). All other
glycomuteins, including rhuEpoGln38, rhuEpoGln83, rhuEpoThr126, and
rhuEpoGly126, were secreted at lower levels than rhuEpowt. Muteins
expressed in stable cell lines showed similar differences in expression
levels. Also each mutein could be affinity-purified from culture
supernatants, and was biologically active in vivo. Based on secretion rates
from BHK-21 cells, the most potent erythropoietin was rhuEpoGln24. This
mutein is also considered to have biologic activities that are superior to
rhuEpowt.
Volume 85,
Issue 5,
pp. 1229-1236,
03/01/1995
Copyright © 1995 by The American Society of Hematology